A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer

G. T. Budd, S. Green, L. H. Baker, Evan M Hersh, J. K. Weick, C. K. Osborne

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

New approaches are needed in the treatment of advanced breast cancer. In vitro studies have shown that recombinant tumor necrosis factor (TNF) is a growth inhibitor for the MCF-7, ZR-75-1, and BT-20 human breast cancer cell lines. Based on these considerations, the Southwest Oncology Group performed a Phase II trial of recombinant TNF (Genentech) (150 μg/m2) given by 30- minute intravenous infusion on days 1 to 5 of every other week for 8 weeks. Patients with metastatic breast cancer who had received one prior chemotherapy regimen for advanced disease were eligible. Of the 22 patients who were entered, 3 were ineligible. Nineteen patients who had a performance status of 2 or less could be examined (median age, 53 years). One possible fatal toxic reaction has been seen in a patient who had intracranial bleeding caused by a previously undiagnosed brain metastasis; no other treatment- related deaths have occurred. Toxicity has included nausea, vomiting, fever, chills, myalgia, and fatigue. No Grade 4 toxicity has been observed. Grade 3 toxic reactions have included hypotension (two patients), diarrhea (one patient), transient leukopenia (two patients), and reversible elevations of liver function test values (two patients). No objective responses have been observed. Twelve of 19 patients have died (median survival time, 8.5 months). Recombinant TNF is inactive as a single agent in patients with previously treated metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)1694-1695
Number of pages2
JournalCancer
Volume68
Issue number8
StatePublished - 1991

Fingerprint

Tumor Necrosis Factor-alpha
Breast Neoplasms
Poisons
Growth Inhibitors
Chills
Liver Function Tests
Myalgia
Leukopenia
Proxy
Intravenous Infusions
Hypotension
Nausea
Vomiting
Fatigue
Diarrhea
Fever
Hemorrhage
Neoplasm Metastasis
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Budd, G. T., Green, S., Baker, L. H., Hersh, E. M., Weick, J. K., & Osborne, C. K. (1991). A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer, 68(8), 1694-1695.

A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. / Budd, G. T.; Green, S.; Baker, L. H.; Hersh, Evan M; Weick, J. K.; Osborne, C. K.

In: Cancer, Vol. 68, No. 8, 1991, p. 1694-1695.

Research output: Contribution to journalArticle

Budd, GT, Green, S, Baker, LH, Hersh, EM, Weick, JK & Osborne, CK 1991, 'A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer', Cancer, vol. 68, no. 8, pp. 1694-1695.
Budd, G. T. ; Green, S. ; Baker, L. H. ; Hersh, Evan M ; Weick, J. K. ; Osborne, C. K. / A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. In: Cancer. 1991 ; Vol. 68, No. 8. pp. 1694-1695.
@article{c437351ca05946bb81bb0841b80dcf57,
title = "A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer",
abstract = "New approaches are needed in the treatment of advanced breast cancer. In vitro studies have shown that recombinant tumor necrosis factor (TNF) is a growth inhibitor for the MCF-7, ZR-75-1, and BT-20 human breast cancer cell lines. Based on these considerations, the Southwest Oncology Group performed a Phase II trial of recombinant TNF (Genentech) (150 μg/m2) given by 30- minute intravenous infusion on days 1 to 5 of every other week for 8 weeks. Patients with metastatic breast cancer who had received one prior chemotherapy regimen for advanced disease were eligible. Of the 22 patients who were entered, 3 were ineligible. Nineteen patients who had a performance status of 2 or less could be examined (median age, 53 years). One possible fatal toxic reaction has been seen in a patient who had intracranial bleeding caused by a previously undiagnosed brain metastasis; no other treatment- related deaths have occurred. Toxicity has included nausea, vomiting, fever, chills, myalgia, and fatigue. No Grade 4 toxicity has been observed. Grade 3 toxic reactions have included hypotension (two patients), diarrhea (one patient), transient leukopenia (two patients), and reversible elevations of liver function test values (two patients). No objective responses have been observed. Twelve of 19 patients have died (median survival time, 8.5 months). Recombinant TNF is inactive as a single agent in patients with previously treated metastatic breast cancer.",
author = "Budd, {G. T.} and S. Green and Baker, {L. H.} and Hersh, {Evan M} and Weick, {J. K.} and Osborne, {C. K.}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "1694--1695",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - A Southwest Oncology Group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer

AU - Budd, G. T.

AU - Green, S.

AU - Baker, L. H.

AU - Hersh, Evan M

AU - Weick, J. K.

AU - Osborne, C. K.

PY - 1991

Y1 - 1991

N2 - New approaches are needed in the treatment of advanced breast cancer. In vitro studies have shown that recombinant tumor necrosis factor (TNF) is a growth inhibitor for the MCF-7, ZR-75-1, and BT-20 human breast cancer cell lines. Based on these considerations, the Southwest Oncology Group performed a Phase II trial of recombinant TNF (Genentech) (150 μg/m2) given by 30- minute intravenous infusion on days 1 to 5 of every other week for 8 weeks. Patients with metastatic breast cancer who had received one prior chemotherapy regimen for advanced disease were eligible. Of the 22 patients who were entered, 3 were ineligible. Nineteen patients who had a performance status of 2 or less could be examined (median age, 53 years). One possible fatal toxic reaction has been seen in a patient who had intracranial bleeding caused by a previously undiagnosed brain metastasis; no other treatment- related deaths have occurred. Toxicity has included nausea, vomiting, fever, chills, myalgia, and fatigue. No Grade 4 toxicity has been observed. Grade 3 toxic reactions have included hypotension (two patients), diarrhea (one patient), transient leukopenia (two patients), and reversible elevations of liver function test values (two patients). No objective responses have been observed. Twelve of 19 patients have died (median survival time, 8.5 months). Recombinant TNF is inactive as a single agent in patients with previously treated metastatic breast cancer.

AB - New approaches are needed in the treatment of advanced breast cancer. In vitro studies have shown that recombinant tumor necrosis factor (TNF) is a growth inhibitor for the MCF-7, ZR-75-1, and BT-20 human breast cancer cell lines. Based on these considerations, the Southwest Oncology Group performed a Phase II trial of recombinant TNF (Genentech) (150 μg/m2) given by 30- minute intravenous infusion on days 1 to 5 of every other week for 8 weeks. Patients with metastatic breast cancer who had received one prior chemotherapy regimen for advanced disease were eligible. Of the 22 patients who were entered, 3 were ineligible. Nineteen patients who had a performance status of 2 or less could be examined (median age, 53 years). One possible fatal toxic reaction has been seen in a patient who had intracranial bleeding caused by a previously undiagnosed brain metastasis; no other treatment- related deaths have occurred. Toxicity has included nausea, vomiting, fever, chills, myalgia, and fatigue. No Grade 4 toxicity has been observed. Grade 3 toxic reactions have included hypotension (two patients), diarrhea (one patient), transient leukopenia (two patients), and reversible elevations of liver function test values (two patients). No objective responses have been observed. Twelve of 19 patients have died (median survival time, 8.5 months). Recombinant TNF is inactive as a single agent in patients with previously treated metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026334942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026334942&partnerID=8YFLogxK

M3 - Article

C2 - 1913510

AN - SCOPUS:0026334942

VL - 68

SP - 1694

EP - 1695

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -